BRPI0814644A2 - Anticorpos para cd200 e usos destes na inibição de respostas imunes. - Google Patents

Anticorpos para cd200 e usos destes na inibição de respostas imunes.

Info

Publication number
BRPI0814644A2
BRPI0814644A2 BRPI0814644-6A2A BRPI0814644A BRPI0814644A2 BR PI0814644 A2 BRPI0814644 A2 BR PI0814644A2 BR PI0814644 A BRPI0814644 A BR PI0814644A BR PI0814644 A2 BRPI0814644 A2 BR PI0814644A2
Authority
BR
Brazil
Prior art keywords
antibodies
inhibiting immune
answers
immune answers
inhibiting
Prior art date
Application number
BRPI0814644-6A2A
Other languages
English (en)
Inventor
Russell P Rother
Susan Faas Micknight
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BRPI0814644A2 publication Critical patent/BRPI0814644A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814644-6A2A 2007-07-25 2008-07-25 Anticorpos para cd200 e usos destes na inibição de respostas imunes. BRPI0814644A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
PCT/US2008/009037 WO2009014745A1 (en) 2007-07-25 2008-07-25 Antibodies to cd200 and uses thereof in inhibiting immune responses

Publications (1)

Publication Number Publication Date
BRPI0814644A2 true BRPI0814644A2 (pt) 2015-01-27

Family

ID=40001380

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814644-6A2A BRPI0814644A2 (pt) 2007-07-25 2008-07-25 Anticorpos para cd200 e usos destes na inibição de respostas imunes.

Country Status (9)

Country Link
US (3) USRE46323E1 (pt)
EP (1) EP2178561A1 (pt)
JP (4) JP2010534243A (pt)
KR (1) KR20100041849A (pt)
AU (1) AU2008279619B2 (pt)
BR (1) BRPI0814644A2 (pt)
CA (1) CA2697159C (pt)
MX (1) MX2010000981A (pt)
WO (1) WO2009014745A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100041849A (ko) * 2007-07-25 2010-04-22 알렉시온 파마슈티칼스, 인코포레이티드 Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도
SG182823A1 (en) * 2010-02-11 2012-09-27 Alexion Pharma Inc Therapeutic methods using an ti-cd200 antibodies
JP6150734B2 (ja) * 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
WO2016097231A2 (en) * 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
CA3004048A1 (en) 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019126536A1 (en) * 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
US20210087267A1 (en) 2017-12-20 2021-03-25 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
EP4296280A1 (en) * 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DE69833779T2 (de) * 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto Verfahren und zusammensetzungen zur immunomodulation
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2004060295A2 (en) 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
NZ599035A (en) * 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
KR20100036362A (ko) 2007-07-25 2010-04-07 알렉시온 파마슈티칼스, 인코포레이티드 자가면역 질환 치료 방법 및 조성물
KR20100041849A (ko) * 2007-07-25 2010-04-22 알렉시온 파마슈티칼스, 인코포레이티드 Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도

Also Published As

Publication number Publication date
US20100291085A1 (en) 2010-11-18
USRE46323E1 (en) 2017-02-28
KR20100041849A (ko) 2010-04-22
JP2010534243A (ja) 2010-11-04
US8252285B2 (en) 2012-08-28
JP2016117762A (ja) 2016-06-30
JP2015172090A (ja) 2015-10-01
MX2010000981A (es) 2010-05-21
JP2013163695A (ja) 2013-08-22
EP2178561A1 (en) 2010-04-28
AU2008279619B2 (en) 2013-11-14
WO2009014745A1 (en) 2009-01-29
US20120321625A1 (en) 2012-12-20
CA2697159C (en) 2017-02-14
AU2008279619A1 (en) 2009-01-29
JP5926702B2 (ja) 2016-05-25
US8637014B2 (en) 2014-01-28
CA2697159A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0814644A2 (pt) Anticorpos para cd200 e usos destes na inibição de respostas imunes.
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI1010540A2 (pt) "anticorpos especéficos para dkk-1 e seus usos"
CY2018018I2 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
BRPI0812005A2 (pt) anticorpos humanizados para o globulômeros de ab(20-42) e seus usos.
CR10466A (es) Anticuerpos e inmunoconjugados y sus usos
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
BR112015014063A2 (pt) anticorpos anti-b7-h4 humano e seus usos.
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
BRPI0815983A2 (pt) anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
DK2176296T3 (da) Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
BRPI0907530A2 (pt) Anticorpos direcionados à angiopoietina-1 angiopoietina-2 e seus usos
BRPI0717638A2 (pt) Anticorpors e imunoconjugados e usos para os mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0815564A2 (pt) Anticorpos que inibem a dimerização de c-met e usos dos mesmos.
BRPI0819598A2 (pt) anticorpos para o antígeno pcrv da pseudomonas aeruginosa
BR112015003838A2 (pt) formulações de anticorpo e proteína
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
ATE496849T1 (de) Getränkeinhaltstoffkapsel
BRPI0906387A2 (pt) Anticorpos alfa 5 - beta 1 e seus usos
BRPI0906498A2 (pt) Anticorpo ron e seus usos
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.